Global Tumor Immunity Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Report ID: GIR2212300167 | Category: Pharma & Healthcare | Pages: 114 | Format: PDF | Published Date: February 06,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3480.00 Multi User-$5220.00

Report Description
View Table of Contents

Report Summary

According to our (Global Info Research) latest study, the global Tumor Immunity Therapy market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Tumor Immunity Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Tumor Immunity Therapy market size and forecasts, in consumption value ($ Million), 2018-2029
Global Tumor Immunity Therapy market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Tumor Immunity Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Tumor Immunity Therapy market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tumor Immunity Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Tumor Immunity Therapy market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc and Sanofi S.A., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Tumor Immunity Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
    Immune Checkpoint Inhibitor
    Cytokine Immunotherapy
    Cancer Vaccine
    Car-t Cell Therapy
    Others
Market segment by Application
    Hospital
    Clinic
Market segment by players, this report covers
    Bristol-Myers Squibb
    Merck & Co., Inc.
    Roche AG
    AstraZeneca, Plc
    Sanofi S.A.
    Dendreon Pharmaceuticals
    Novartis
    Gilead Sciences Inc.
    IMVAQ Therapeutics
    Arch Oncology
    Juno Therapeutics
    Refuge
    Lepu Biopharma
    Genoimmune
    TCR Cure
Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Tumor Immunity Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Tumor Immunity Therapy, with revenue, gross margin and global market share of Tumor Immunity Therapy from 2018 to 2023.
Chapter 3, the Tumor Immunity Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Tumor Immunity Therapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Tumor Immunity Therapy.
Chapter 13, to describe Tumor Immunity Therapy research findings and conclusion.

1 Market Overview
    1.1 Product Overview and Scope of Tumor Immunity Therapy
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Tumor Immunity Therapy by Type
        1.3.1 Overview: Global Tumor Immunity Therapy Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Tumor Immunity Therapy Consumption Value Market Share by Type in 2022
        1.3.3 Immune Checkpoint Inhibitor
        1.3.4 Cytokine Immunotherapy
        1.3.5 Cancer Vaccine
        1.3.6 Car-t Cell Therapy
        1.3.7 Others
    1.4 Global Tumor Immunity Therapy Market by Application
        1.4.1 Overview: Global Tumor Immunity Therapy Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Hospital
        1.4.3 Clinic
    1.5 Global Tumor Immunity Therapy Market Size & Forecast
    1.6 Global Tumor Immunity Therapy Market Size and Forecast by Region
        1.6.1 Global Tumor Immunity Therapy Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Tumor Immunity Therapy Market Size by Region, (2018-2029)
        1.6.3 North America Tumor Immunity Therapy Market Size and Prospect (2018-2029)
        1.6.4 Europe Tumor Immunity Therapy Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Tumor Immunity Therapy Market Size and Prospect (2018-2029)
        1.6.6 South America Tumor Immunity Therapy Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Tumor Immunity Therapy Market Size and Prospect (2018-2029)
2 Company Profiles
    2.1 Bristol-Myers Squibb
        2.1.1 Bristol-Myers Squibb Details
        2.1.2 Bristol-Myers Squibb Major Business
        2.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Product and Solutions
        2.1.4 Bristol-Myers Squibb Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans
    2.2 Merck & Co., Inc.
        2.2.1 Merck & Co., Inc. Details
        2.2.2 Merck & Co., Inc. Major Business
        2.2.3 Merck & Co., Inc. Tumor Immunity Therapy Product and Solutions
        2.2.4 Merck & Co., Inc. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Merck & Co., Inc. Recent Developments and Future Plans
    2.3 Roche AG
        2.3.1 Roche AG Details
        2.3.2 Roche AG Major Business
        2.3.3 Roche AG Tumor Immunity Therapy Product and Solutions
        2.3.4 Roche AG Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Roche AG Recent Developments and Future Plans
    2.4 AstraZeneca, Plc
        2.4.1 AstraZeneca, Plc Details
        2.4.2 AstraZeneca, Plc Major Business
        2.4.3 AstraZeneca, Plc Tumor Immunity Therapy Product and Solutions
        2.4.4 AstraZeneca, Plc Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 AstraZeneca, Plc Recent Developments and Future Plans
    2.5 Sanofi S.A.
        2.5.1 Sanofi S.A. Details
        2.5.2 Sanofi S.A. Major Business
        2.5.3 Sanofi S.A. Tumor Immunity Therapy Product and Solutions
        2.5.4 Sanofi S.A. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Sanofi S.A. Recent Developments and Future Plans
    2.6 Dendreon Pharmaceuticals
        2.6.1 Dendreon Pharmaceuticals Details
        2.6.2 Dendreon Pharmaceuticals Major Business
        2.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Product and Solutions
        2.6.4 Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Dendreon Pharmaceuticals Recent Developments and Future Plans
    2.7 Novartis
        2.7.1 Novartis Details
        2.7.2 Novartis Major Business
        2.7.3 Novartis Tumor Immunity Therapy Product and Solutions
        2.7.4 Novartis Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Novartis Recent Developments and Future Plans
    2.8 Gilead Sciences Inc.
        2.8.1 Gilead Sciences Inc. Details
        2.8.2 Gilead Sciences Inc. Major Business
        2.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Product and Solutions
        2.8.4 Gilead Sciences Inc. Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Gilead Sciences Inc. Recent Developments and Future Plans
    2.9 IMVAQ Therapeutics
        2.9.1 IMVAQ Therapeutics Details
        2.9.2 IMVAQ Therapeutics Major Business
        2.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Product and Solutions
        2.9.4 IMVAQ Therapeutics Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 IMVAQ Therapeutics Recent Developments and Future Plans
    2.10 Arch Oncology 
        2.10.1 Arch Oncology Details
        2.10.2 Arch Oncology Major Business
        2.10.3 Arch Oncology Tumor Immunity Therapy Product and Solutions
        2.10.4 Arch Oncology Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 Arch Oncology Recent Developments and Future Plans
    2.11 Juno Therapeutics
        2.11.1 Juno Therapeutics Details
        2.11.2 Juno Therapeutics Major Business
        2.11.3 Juno Therapeutics Tumor Immunity Therapy Product and Solutions
        2.11.4 Juno Therapeutics Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.11.5 Juno Therapeutics Recent Developments and Future Plans
    2.12 Refuge
        2.12.1 Refuge Details
        2.12.2 Refuge Major Business
        2.12.3 Refuge Tumor Immunity Therapy Product and Solutions
        2.12.4 Refuge Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.12.5 Refuge Recent Developments and Future Plans
    2.13 Lepu Biopharma
        2.13.1 Lepu Biopharma Details
        2.13.2 Lepu Biopharma Major Business
        2.13.3 Lepu Biopharma Tumor Immunity Therapy Product and Solutions
        2.13.4 Lepu Biopharma Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.13.5 Lepu Biopharma Recent Developments and Future Plans
    2.14 Genoimmune
        2.14.1 Genoimmune Details
        2.14.2 Genoimmune Major Business
        2.14.3 Genoimmune Tumor Immunity Therapy Product and Solutions
        2.14.4 Genoimmune Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.14.5 Genoimmune Recent Developments and Future Plans
    2.15 TCR Cure
        2.15.1 TCR Cure Details
        2.15.2 TCR Cure Major Business
        2.15.3 TCR Cure Tumor Immunity Therapy Product and Solutions
        2.15.4 TCR Cure Tumor Immunity Therapy Revenue, Gross Margin and Market Share (2018-2023)
        2.15.5 TCR Cure Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Global Tumor Immunity Therapy Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Tumor Immunity Therapy by Company Revenue
        3.2.2 Top 3 Tumor Immunity Therapy Players Market Share in 2022
        3.2.3 Top 6 Tumor Immunity Therapy Players Market Share in 2022
    3.3 Tumor Immunity Therapy Market: Overall Company Footprint Analysis
        3.3.1 Tumor Immunity Therapy Market: Region Footprint
        3.3.2 Tumor Immunity Therapy Market: Company Product Type Footprint
        3.3.3 Tumor Immunity Therapy Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
    4.1 Global Tumor Immunity Therapy Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Tumor Immunity Therapy Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
    5.1 Global Tumor Immunity Therapy Consumption Value Market Share by Application (2018-2023)
    5.2 Global Tumor Immunity Therapy Market Forecast by Application (2024-2029)
6 North America
    6.1 North America Tumor Immunity Therapy Consumption Value by Type (2018-2029)
    6.2 North America Tumor Immunity Therapy Consumption Value by Application (2018-2029)
    6.3 North America Tumor Immunity Therapy Market Size by Country
        6.3.1 North America Tumor Immunity Therapy Consumption Value by Country (2018-2029)
        6.3.2 United States Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        6.3.3 Canada Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        6.3.4 Mexico Tumor Immunity Therapy Market Size and Forecast (2018-2029)
7 Europe
    7.1 Europe Tumor Immunity Therapy Consumption Value by Type (2018-2029)
    7.2 Europe Tumor Immunity Therapy Consumption Value by Application (2018-2029)
    7.3 Europe Tumor Immunity Therapy Market Size by Country
        7.3.1 Europe Tumor Immunity Therapy Consumption Value by Country (2018-2029)
        7.3.2 Germany Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        7.3.3 France Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        7.3.5 Russia Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        7.3.6 Italy Tumor Immunity Therapy Market Size and Forecast (2018-2029)
8 Asia-Pacific
    8.1 Asia-Pacific Tumor Immunity Therapy Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Tumor Immunity Therapy Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Tumor Immunity Therapy Market Size by Region
        8.3.1 Asia-Pacific Tumor Immunity Therapy Consumption Value by Region (2018-2029)
        8.3.2 China Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        8.3.3 Japan Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        8.3.4 South Korea Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        8.3.5 India Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        8.3.7 Australia Tumor Immunity Therapy Market Size and Forecast (2018-2029)
9 South America
    9.1 South America Tumor Immunity Therapy Consumption Value by Type (2018-2029)
    9.2 South America Tumor Immunity Therapy Consumption Value by Application (2018-2029)
    9.3 South America Tumor Immunity Therapy Market Size by Country
        9.3.1 South America Tumor Immunity Therapy Consumption Value by Country (2018-2029)
        9.3.2 Brazil Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        9.3.3 Argentina Tumor Immunity Therapy Market Size and Forecast (2018-2029)
10 Middle East & Africa
    10.1 Middle East & Africa Tumor Immunity Therapy Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Tumor Immunity Therapy Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Tumor Immunity Therapy Market Size by Country
        10.3.1 Middle East & Africa Tumor Immunity Therapy Consumption Value by Country (2018-2029)
        10.3.2 Turkey Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Tumor Immunity Therapy Market Size and Forecast (2018-2029)
        10.3.4 UAE Tumor Immunity Therapy Market Size and Forecast (2018-2029)
11 Market Dynamics
    11.1 Tumor Immunity Therapy Market Drivers
    11.2 Tumor Immunity Therapy Market Restraints
    11.3 Tumor Immunity Therapy Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
    12.1 Tumor Immunity Therapy Industry Chain
    12.2 Tumor Immunity Therapy Upstream Analysis
    12.3 Tumor Immunity Therapy Midstream Analysis
    12.4 Tumor Immunity Therapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global Tumor Immunity Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?